PERSPECTIVE FROM THE 19TH HOLE: This is the title I chose for my personal blog, which is meant to give me an outlet for one of my favorite crafts – writing – plus to use an image from my favorite sport, golf. Out of college, my first job was as a reporter for the Daily Astorian in Astoria, Oregon, and I went on from there to practice writing in all of my professional positions, including as press secretary in Washington, D.C. for a Democrat Congressman from Oregon, as an Oregon state government manager in Salem and Portland, as press secretary for Oregon’s last Republican governor (Vic Atiyeh), and as a private sector lobbyist. This blog also allows me to link another favorite pastime – politics and the art of developing public policy – to what I write.
I wrote the other day about the real solution to the coronavirus pandemic, which any reasonably smart person would know – that includes me, I attest — is vaccines.
The good news is that several are in various stages of development and the normal time frame for such development – 12-18 months – could be shortened, given the extremity of the world’s circumstance.
Hill.com reported on four major efforts by pharmaceutical companies to move on vaccines around the world, often, but not always, with government help.
Over the weekend, the Wall Street Journal (WSJ) showed up with a story — excerpts below — that provides more information, including background on a tough, but real, issue – who gets vaccines first and how long it might take for vaccines to be available generally.
The WSJ story appeared under this headline:
Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed
Drug-makers build capacity to make hundreds of millions of doses, while authorities discuss: Who will get it first?
Here are more excerpts.
*********
Governments and drug-makers are weighing how to roll out coronavirus vaccines, including reserving the first batches for health-care workers, as several shots race to early leads.
Of more than 100 vaccines in development globally, at least eight have started testing in humans, including candidates from Moderna Inc. and Pfizer Inc. At the same time, pharmaceutical giants like Johnson & Johnson, AstraZeneca PLC and Sanofi SA are building capacity to make hundreds of millions of doses of their own or their partners’ vaccines.
The efforts are part of a larger rush, including at the White House, to line up funding for accelerated testing and expanded manufacturing capacity, all to make doses available in the U.S. starting as soon as this fall.
Yet, there isn’t a guarantee that any of the most advanced vaccine candidates will prove to work safely on such a short timetable. Some, like vaccines from Pfizer and Moderna, are based on relatively new technologies that haven’t been approved previously.
Once a vaccine is proved in clinical testing to work safely, drug makers expect the U.S. Food and Drug Administration would move quickly to permit its use, even if the agency doesn’t have all the evidence it typically collects before granting an approval.
The FDA authorized such an emergency use of the drug remdesivir from Gilead Sciences Inc., for treating hospitalized Covid-19 patients on May 1, days after a study showed it shortened hospital stays.
Several drug makers that have been building up their capabilities to make coronavirus vaccines also have pledged to deliver millions of doses this year. Yet, a fuller supply to vaccinate the general population might not become available until well into 2021, according to company projections and estimates by vaccine experts.
“Ideally we’d want seven or eight billion doses the day after licensure, so we can vaccinate the whole world,” said Walter Orenstein, associate director of Emory University’s vaccine center in Atlanta. “The likelihood is we won’t have enough to vaccinate even the entire U.S. population” when a vaccine first becomes available, he said.
The non-profit Coalition for Epidemic Preparedness Innovations, which promotes the equitable allocation of vaccines around the globe, recently agreed to give more than $380 million to Novavax Inc. to help develop a vaccine that would be made in various countries for distribution world-wide.
Groups likely to be at the head of the line for access are front-line health-care workers and first responders, plus essential workers like grocery, pharmacy, food-supply and mass-transit employees, said Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, who serves on a committee with federal and drug-industry officials that is trying to accelerate coronavirus vaccine development.
Johnson & Johnson expects to have some batches of its vaccine ready by early 2021, which Chief Scientific Officer Paul Stoffels said should be sufficient to vaccinate health-care workers globally. The company expects to eventually make more than a billion doses.
Moderna is expanding its vaccine production capacity, including via a partnership with Swiss contract manufacturer Lonza Ltd., to make tens of millions of doses a month by the end of this year, and eventually as many as one billion doses a year, said Chief Executive Stephane Bancel.
One open question is whether the elderly will benefit from a coronavirus vaccine. Immune systems decline with age, which can reduce vaccines’ effectiveness in older adults.
**********
I say full bore ahead with vaccine development. It is the only way we get back to any sense of normalcy.